ViiV Healthcare Cabenuva Meets Primary Endpoint in Phase IIIb CROWN Study of People With HIV Viremia
ViiV Healthcare Cabenuva (cabotegravir + rilpivirine) met the primary endpoint of the phase IIIb CROWN study, with superior six-month viral suppression versus standard oral ART in people with detectable HIV. The use is investigational and not approved.
AbbVie and Genmab Announce Epcoritamab R-CHOP Cuts Progression Risk by 51% in Newly Diagnosed DLBCL in Phase 3 EPCORE DLBCL-2 Trial
AbbVie and Genmab report that Epcoritamab R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, in the Phase 3 EPCORE DLBCL-2 trial. The combination remains investigational.
Eyestem Reports Eyecyte-RPE Phase 2 Interim Data at EURetina 2026, Showing Continuing Visual Acuity Gains in Geographic Atrophy
Eyestem presented interim Eyecyte-RPE Phase 2 data at EURetina 2026 in Vienna. The data show continuing visual acuity gains in geographic atrophy, an excellent safety profile, and a US IND filing planned for early 2027.
Eli Lilly Secures FDA Jaypirca Approval for Pirtobrutinib in Previously Untreated CLL/SLL
Eli Lilly announced the Jaypirca Approval on October 2, 2026, as the FDA cleared pirtobrutinib for adults with previously untreated CLL/SLL and no known 17p deletion.
Pfizer LITFULO Vitiligo Phase 3 Results: Ritlecitinib Improves Facial and Total Body Repigmentation at EADV
Pfizer LITFULO vitiligo Phase 3 results from TRANQUILLO 2 and TRANQUILLO show significant facial and total body repigmentation versus placebo at Week 52, supporting planned FDA and EMA submissions.
Sanofi Regeneron Alliance Expansion Adds Four Long-Acting Immunology Antibodies, Including REGN20423, in $1 Billion Upfront Deal
The Sanofi Regeneron Alliance Expansion adds four long-acting, Regeneron-invented immunology antibodies to the Dupixent partnership. Regeneron receives $1 billion upfront, with up to $7 billion more in potential milestones and a 50:50 profit split.
AbbVie ABBV-295 Phase 1 Data Show Long-Acting Potential for Obesity Treatment at EASD 2026
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
Novo Nordisk Reports CagriSema EASD 2026 Data Showing Reduced ‘Food Noise’ and Organ and Bone Health Benefits
Novo Nordisk presented CagriSema EASD 2026 data showing changed brain responses to food cues, reduced ‘food noise’, less fat around abdominal organs and preliminary bone reassurance in adults with obesity or type 2 diabetes.
Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.
The Roche fenebrutinib FDA filing has been accepted under priority review for relapsing and primary progressive multiple sclerosis. The application draws on the FENhance 1, FENhance 2 and FENtrepid Phase III studies.
Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026
Novo presented COMPETE SWITCH CV real-world data at EASD 2026. Adults with type 2 diabetes who escalated from Ozempic 1 mg to 2 mg were associated with a 6% lower MACE risk than those who switched to Mounjaro.